Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Continuing Operations (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Income from Continuing Operations for 4 consecutive years, with 25287000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 61.5% to 25287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 111255000.0 through Dec 2025, up 45.63% year-over-year, with the annual reading at 111274000.0 for FY2025, 16.58% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 25287000.0 at Day One Biopharmaceuticals, down from 19692000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 35840000.0 in Q3 2024, with the low at 112397000.0 in Q2 2024.
  • Average Income from Continuing Operations over 4 years is 40433375.0, with a median of 38943500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations surged 177.66% in 2024, then plummeted 154.94% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 40083000.0 in 2022, then crashed by 35.95% to 54493000.0 in 2023, then dropped by 20.53% to 65680000.0 in 2024, then skyrocketed by 61.5% to 25287000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 25287000.0, 19692000.0, and 30303000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.